Understanding how immune cells contribute to lung damage in cystic fibrosis
Pathogenic monocyte response to chronic lung inflammation in cystic fibrosis
This study is looking at how certain immune cells called inflammatory monocytes might be causing lung damage in people with cystic fibrosis, using a mouse model to understand their role better and find new ways to help improve lung health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10994153 on NIH RePORTER |
What this research studies
This research investigates the role of inflammatory monocytes in causing lung damage in patients with cystic fibrosis (CF). Using a mouse model that mimics chronic lung inflammation seen in CF, researchers aim to uncover how these immune cells contribute to irreversible lung tissue remodeling. The study focuses on the mechanisms by which monocytes are recruited to the lungs and how they may inadvertently cause more harm than good in fighting infections. By examining changes in these cells over time, the research seeks to identify potential targets for therapeutic intervention.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis who experience chronic lung inflammation.
Not a fit: Patients without cystic fibrosis or those with early-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent lung damage and improve respiratory function in cystic fibrosis patients.
How similar studies have performed: Previous studies have shown that targeting inflammatory pathways can lead to improvements in lung function in other chronic respiratory diseases, suggesting potential for success in this area as well.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Bruscia, Emanuela Marina — Yale University
- Study coordinator: Bruscia, Emanuela Marina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.